How Much Weight Are People Losing on Mounjaro?

Last reviewed: July 15, 2026

Last updated: July 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide has emerged as one of the most studied dual-action GLP-1 receptor agonist and GIP receptor agonist compounds available, with clinical trials demonstrating average weight loss of 20–22% of baseline body weight. Real patient outcomes vary based on starting weight, adherence, lifestyle factors, and individual metabolic response. PlexusDx helps you access compounded tirzepatide and personalize your therapy using genetic insights.

Clinical Trial Weight Loss Data for Tirzepatide

The SURPASS clinical trial program evaluated tirzepatide across multiple dose levels in people with obesity and type 2 diabetes. Participants receiving the highest maintenance dose (15 mg weekly) lost an average of 22.5% of their baseline body weight by week 68—substantially more than those on placebo or competing GLP-1 compounds. These results held across diverse populations including those with cardiovascular disease, chronic kidney disease, and metabolic syndrome.

Weight loss trajectories typically follow a pattern: most meaningful loss occurs in months 2–6, with continued gradual reduction through month 12 and beyond. A substantial portion of patients achieved 15–20% body weight reduction, while approximately one-third reached 25% or greater reductions. Importantly, weight regain is less common when patients maintain consistent medication adherence and lifestyle modifications.

Real-World Tirzepatide Outcomes Outside Clinical Trials

Observational data from clinical practices and telemedicine platforms show that average weight loss on tirzepatide ranges from 15–24% of starting body weight over 12 months, with individual variation tied to dose tolerance, baseline metabolic rate, and diet consistency. Some users experience more rapid loss in the first three months, while others see steady progress over the entire year. Factors like age, sex, baseline insulin resistance, and previous weight loss medication experience all influence personal outcomes.

Patient-reported results often include unexpected benefits beyond the scale: improved energy levels, reduced food cravings, better blood sugar control, and enhanced appetite regulation. These secondary improvements frequently drive long-term adherence and sustained weight management. Real-world efficacy is lower than peak trial results partly because not all patients reach the highest maintenance doses due to gastrointestinal tolerability or personal preference.

Factors That Influence Individual Tirzepatide Weight Loss Results

Genetic variation in peptide receptor pathways plays a measurable role in how your body responds to tirzepatide. Key genetic variants—including GLP1R, GIPR, FTO, and MC4R—influence appetite regulation, metabolic rate, and satiety signaling. PlexusDx Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptide-related variants, helping you understand your genetic predispositions and optimize compound selection and dosing strategy before you start.

Behavioral factors like meal composition, physical activity frequency, sleep quality, and stress management directly impact weight loss velocity on tirzepatide. Starting weight also matters: individuals with higher baseline body mass index (BMI) often experience larger absolute weight reductions, though percentage loss may be comparable. Medication timing, injection site rotation, and consistent weekly dosing schedules maximize the compound's effectiveness and minimize week-to-week variability in appetite suppression.

PlexusDx Compounded Tirzepatide vs. Brand-Name Options

PlexusDx delivers tirzepatide from licensed 503A compounding pharmacies, making therapy accessible without insurance and at a flat rate at $289/mo month-to-month, or from $249/mo on the 6-month plan—your dose may need to go up, but your price won't. All compounded formulations undergo rigorous quality testing for sterility, potency, and purity, meeting USP standards. Compounded tirzepatide offers the same active pharmaceutical ingredient as brand products but removes the cost and insurance barriers that prevent many people from accessing GLP-1 therapy.

PlexusDx also offers oral tirzepatide (at $349/mo month-to-month, or from $279/mo on the 6-month plan) for patients who prefer tablets to injections. Both forms are available in all 50 states without a membership fee, with HSA and FSA eligibility. If you want to combine two GLP-1 compounds for synergistic effect, PlexusDx GLP-Squared Injection (semaglutide + tirzepatide dual compound) is $289/mo month-to-month (or $249/mo on the 3-month plan), offering a research-backed alternative approach to maximizing metabolic impact.

Setting Realistic Weight Loss Expectations on Tirzepatide

A reasonable first-year target on tirzepatide is 15–22% of your starting body weight, though faster initial loss in months 1–3 is common as appetite suppression kicks in. If you weigh 250 pounds at baseline, expect a realistic outcome range of 37–55 pounds over 12 months of consistent use. These are clinical estimates; actual results depend on adherence, lifestyle, genetic response, and whether you reach a maintenance dose that feels tolerable for your body.

Plateau periods are normal and don't signal treatment failure—metabolic adaptation, reduced caloric deficit, or need for dose adjustment can cause temporary stalls. Many users benefit from reviewing their protein intake, increasing movement, or working with PlexusDx support to fine-tune their dosing schedule. Long-term weight maintenance on tirzepatide (beyond year one) typically requires ongoing medication use; discontinuation often leads to gradual weight regain over months.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose in the first month on tirzepatide?

Most users experience 3–8 pounds of weight loss in month one, primarily from reduced appetite and lower caloric intake. The compound reaches steady state after about four weeks, so continued loss accelerates in months two and three. Individual variation is wide; some people lose more while others progress more gradually depending on starting dose and metabolic factors.

What does the clinical evidence say about tirzepatide for weight loss?

The SURPASS trial series demonstrated that tirzepatide (at 15 mg weekly) produced 22.5% average body weight loss over 68 weeks in people with obesity, outperforming semaglutide and other GLP-1 compounds. Results were consistent across age groups, sexes, and baseline health conditions. Real-world data from telemedicine and clinical practices confirm these reductions are achievable outside controlled trial settings.

How much does PlexusDx compounded tirzepatide cost?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) at the lowest commitment tier with flat pricing — your dose may go up, but your price won't—your dose may need to go up, your price won't. No insurance is required, no membership fee applies, and the medication is HSA/FSA eligible and available in all 50 states.

Are tirzepatide injections safe for long-term weight loss?

Tirzepatide has a well-established safety profile in clinical trials extending up to 18 months, with the most common side effects being mild gastrointestinal symptoms that often resolve with time. Serious adverse events are rare. Ongoing medical supervision and monitoring for pancreatitis risk, gallbladder issues, and thyroid changes is recommended, especially during dose escalation phases.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro For Losing Weight
• Glp 1 For Losing Weight
• Zepbound For Losing Weight
• Ozempic For Losing Weight

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.